Back to articles

Atomoxetine Creates Excitement in ADHD Community


An effective and safe agent for attention-deficit/hyperactivity disorder (ADHD) that is not a controlled substance— that is what clinicians, parents, and patients now have access to in the form of atomoxetine hydrochloride (Strattera— Lilly). Approved by FDA in late November, the selective norepinephrine reuptake inhibitor is the first new drug approved for ADHD in 3 decades, and some experts are predicting that it will snare 25% of the ADHD medication market.


Michelson D et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics. 2001;108:e83.

Michelson D et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry. 2002;159:1896–901.

Kratochvil CJ et al. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. J Am Acad Child Adolesc Psychiatry. 2002;41:776–84.

Biederman J et al. Efficacy of atomoxetine versus placebo in school-age girls with attention-deficit/hyperactivity disorder. Pediatrics. 2002;110:e75.